InfoDesk

AI is becoming part of the everyday reality of Regulatory Intelligence teams in life sciences organizations. What once felt experimental is now supporting practical work across monitoring, triage and interpretation, summarization, impact assessment, communication, and workflow management.

What is decision intelligence and why is it important? Decision intelligence connects regulatory and quality intelligence to action. It ensures that signals identified through regulatory surveillance are assessed, translated into impact, and carried through to decisions and operational change. In life sciences, this shift reflects a broader change in how regulatory and quality teams operate. Intelligence is no longer limited to monitoring or inspection readiness.

At the RAPS Regulatory Intelligence Conference in March 2026, regulatory and quality intelligence leaders from Moderna, Vertex Pharmaceuticals, Regeneron, and UCB discussed how their organizations are building and operationalizing quality intelligence programs. This article is a summary of that discussion. There’s a quiet but significant transformation in life sciences regulatory and GxP compliance programs. Quality intelligence is finding its place in life sciences decision-making intelligence.

Insights from the RAPS Regulatory Intelligence Conference 2026 Insights from a keynote by Barbara Bovy, Head of Quality, Regulatory Intelligence and QMS at UCB, and Brett Bonner, Chief Product & Technology Officer at Infodesk, presented at the RAPS Regulatory Intelligence Conference in Baltimore on March 3, 2026. Regulatory and quality intelligence teams are doing the same core work: gathering signals, connecting the dots, interpreting what they mean, and deciding how to respond.

Regulatory change is constant in the pharmaceutical industry. New guidance, revised standards, and evolving expectations from health authorities shape how medicines are developed, approved, and maintained on the market. When regulators introduce new policies or requirements, they do not always fully account for the operational impact on pharmaceutical organizations. Regulatory impact assessments help bridge that gap.

Regulatory affairs teams play a central role in ensuring medicines are approved, compliant, and sustainable on the market, without slowing innovation. In the pharmaceutical industry, Regulatory Affairs (RA) acts as the bridge between drug companies and health authorities, translating regulatory requirements into practical action across the entire product lifecycle. Regulatory compliance is a shared, cross-functional responsibility supported by governance frameworks and quality systems.

Regulatory compliance in the pharmaceutical industry exists to protect patient safety, ensure product quality, and maintain public trust. Because medicines directly affect human health, regulators impose strict requirements across the entire product lifecycle – from discovery and clinical trials through manufacturing, distribution, and post-market surveillance. Regulatory compliance is not a one-time checklist. It is a continuous, enterprise-wide discipline.

At Infodesk we run a regular workshop as a webinar with existing customers to provide this community with insights into how to find more value from using Infodesk. This week the latest Infodesk customer forum looked at how customers use Infodesk to achieve intelligence activation, to go beyond monitoring and delivering regulatory, market and competitive information to structuring, tagging, and managing content so it can be acted on quickly and confidently.

As teams plan for 2026, in December 2025, we surveyed our customers to identify key issues, concerns, threats, and opportunities shaping regulatory intelligence (RI) teams in life sciences for 2026. This article summarizes our findings. Increased AI adoption in regulatory intelligence Our survey revealed that AI is viewed as the most significant opportunity for RI teams in 2026, with all respondents planning to increase their AI usage.

GxP stands for “Good x Practice,” where ‘x’ represents specific operational areas like Manufacturing (GMP), Laboratory (GLP), and Clinical (GCP). GxP compliance is a framework of quality regulations designed to ensure the safety, efficacy, and quality of products in life sciences, particularly pharmaceuticals, biotech, and medical devices. GxP enforcement is global.